Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RPA1 | P27694 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2314305 | 0.82 | MAPT (0.45) | HSD11B1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13458074 | 0.82 | SMN1; SMN2 (0.47) | MAPTCASP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL928222 | 0.82 | METAP2 (0.39) | HSD11B1MAPTMETAP2NPC1RAB9A | |
| SCHEMBL1686039 | 0.82 | RAB9A (0.52) | HSD11B1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3152568 | 0.82 | KDM4E (0.42) | HSD11B1MAPTMETAP2NPC1RAB9A | |
| SCHEMBL930699 | 0.82 | CASP1 (0.45) | HSD11B1MAPTMETAP2CASP1NPC1 | |
| SCHEMBL29664672 | 0.82 | RAB9A (0.52) | HSD11B1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23731087 | 0.81 | CYP1A2 (0.64) | MAPTNPC1RAB9ASMN1; SMN2MAOB | |
| SCHEMBL240423 | 0.81 | RAB9A (0.50) | CASP1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30402035 | 0.81 | RAB9A (0.50) | CASP1NPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624166-B1 | Pharmaceutical compositions containing the compounds; and a method for inhibiting interleukin-1 beta protease activity in a mammal utilizing the compounds and compositions for enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-23 | — | — | US | claimed |
| EP-2611771-B1 | SUBSTITUTED HETEROARYL- AND ARYLALKYNYL BENZENE DERIVATIVES AS ACC-INHIBITORS FOR THE TREATMENT OF METABOLIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-11-23 | — | — | EP | disclosed |
| EP-2794586-B1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-04-20 | — | — | EP | disclosed |
| EP-2794586-B1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2016-04-20 | — | — | EP | disclosed |
| EP-2797884-B1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-2797884-B1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2016-04-13 | — | — | EP | disclosed |
| EP-2797884-A1 | NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Boehringer Ingelheim International GmbH (DE) | 2014-11-05 | — | — | EP | disclosed |
| EP-2794586-A1 | NEW AZIRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| CN-104093705-A | New azetidine derivatives, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INT | 2014-10-08 | — | — | CN | disclosed |
| US-8835472-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| EP-1558578-A1 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| EP-1474401-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| US-20040209865-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004039780-A1 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-13 | — | — | WO | disclosed |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
| WO-2003066604-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2003-08-14 | — | — | WO | disclosed |
| CN-1075477-A | N-cyanopyridazinones having herbicidal activity | AGROLINZ AGRARCHEMIKALIEN (AT) | 1993-08-25 | — | — | CN | disclosed |
| US-4117130-A | 6-PHENYL-1,2,4-TRIAZOLO(4,3-B)PYRIDAZINES | AMERICAN CYANAMID COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
| US-4112095-A | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents | AMERICAN CYANAMID COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4092311-A | Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates | AMERICAN CYANAMID COMPANY (US) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HRH3, HRH2, HRH4 | HSD11B1 1800/4885MAPT 2646/4885METAP2 723/4885 |
| US-20040209865-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MCHR2, NPY1R | HSD11B1 1324/4885MAPT 4593/4885METAP2 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.